What it's for (Indications)
- Mupirocin (Example brand: Bactroban Cream) is indicated for the topical treatment of impetigo due to *Staphylococcus aureus* (including methicillin-resistant strains) and *Streptococcus pyogenes*.
- It is a broad-spectrum topical antibacterial agent specifically formulated for cutaneous infections where localized bacterial growth is the primary pathology.
- The cream formulation is suitable for skin surface infections and helps in reducing the bacterial load at the site of infection, thereby facilitating the healing process.
- Its application should be restricted to the specific infections for which it is indicated to prevent the emergence of antibiotic resistance.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For adults and pediatric patients 3 months of age and older, a small amount of mupirocin cream should be applied to the affected area three times a day for 3 to 5 days. The treated area may be covered with a sterile gauze dressing if desired. Clinical efficacy beyond 10 days has not been established, and prolonged use is generally not recommended due to the potential for overgrowth of non-susceptible organisms. Patients should be instructed to wash their hands before and after applying the medication, and to avoid contact with eyes, nose, and mouth. Adherence to the prescribed duration of treatment is critical, even if symptoms improve earlier, to ensure complete eradication of the infection and minimize the risk of recurrence or development of resistance. |
Safety & Warnings
Common Side Effects
- Common side effects associated with topical mupirocin cream application include burning, stinging, itching, pain, and dryness at the application site.
- Other reported local reactions may include tenderness, erythema, swelling, contact dermatitis, and increased exudate.
- Less commonly, systemic side effects such as nausea, headache, dizziness, and rash have been noted, though generally mild and transient due to minimal systemic absorption.
- Serious but rare adverse effects include systemic allergic reactions (e.
- g.
- , generalized rash, urticaria, angioedema, anaphylaxis) and *Clostridioides difficile*-associated diarrhea (CDAD), which, though highly uncommon with topical administration, should be considered in patients developing severe, persistent diarrhea.
- Patients should be advised to discontinue use and consult a healthcare professional if severe irritation or allergic reactions occur.
Serious Warnings
- Black Box Warning: **Serious Warnings:** While mupirocin (Bactroban Cream) does not carry an official FDA Black Box Warning, several critical safety considerations warrant meticulous attention. Hypersensitivity reactions, encompassing systemic allergic responses such as angioedema, generalized rash, urticaria, and in rare instances, anaphylaxis, have been reported following mupirocin use. Patients experiencing any signs of sensitization or severe local irritation, including severe itching, burning, or swelling, should immediately discontinue the medication and seek medical advice, as these reactions can be severe. Furthermore, prolonged or inappropriate use of mupirocin can lead to the overgrowth of non-susceptible organisms, including fungi, necessitating prompt discontinuation and initiation of alternative appropriate antimicrobial or antifungal therapy if superinfection occurs. Although systemic absorption of topical mupirocin is minimal, *Clostridioides difficile*-associated diarrhea (CDAD) has been reported with the use of various antibacterial agents and should be considered in the differential diagnosis of patients presenting with severe or persistent diarrhea during or after mupirocin therapy, especially if accompanied by abdominal pain and fever. Healthcare providers must ensure comprehensive patient education regarding proper application, potential adverse effects, and when to seek immediate medical attention.
- Mupirocin cream is for external use only and should not be used in the eyes or applied to mucous membranes, including the nasal mucosa (for which a specific nasal ointment formulation exists).
- Avoid contact with eyes; if accidental contact occurs, rinse thoroughly with water.
- Prolonged use of mupirocin may result in the overgrowth of non-susceptible organisms, including fungi, necessitating discontinuation and initiation of appropriate therapy if superinfection occurs.
- Hypersensitivity reactions, including severe systemic reactions like angioedema and generalized rash, have been reported.
- If a sensitization or severe local irritation reaction occurs, treatment should be discontinued, and the patient appropriately managed.
- *Clostridioides difficile*-associated diarrhea (CDAD) has been reported with the use of nearly all antibacterial agents, including mupirocin, and may range in severity from mild diarrhea to fatal colitis.
- Although CDAD is rare with topical mupirocin, it is important to consider this diagnosis in patients presenting with diarrhea during or after treatment.
How it Works (Mechanism of Action)
Mupirocin is a novel antibacterial agent produced by *Pseudomonas fluorescens*. Its mechanism of action involves the reversible inhibition of bacterial isoleucyl-tRNA synthetase (IleRS), an enzyme essential for the incorporation of isoleucine into bacterial proteins. This unique mode of action distinguishes it from other antibacterial agents and contributes to its low potential for cross-resistance with other classes of antibiotics. By inhibiting bacterial protein synthesis, mupirocin effectively halts bacterial growth and replication. It demonstrates bacteriostatic activity at lower concentrations and bactericidal activity at higher concentrations, making it highly effective against susceptible gram-positive bacteria, including *Staphylococcus aureus* (both methicillin-susceptible and methicillin-resistant strains) and *Streptococcus pyogenes*, which are common causative agents of skin infections like impetigo.
Commercial Brands (Alternatives)
No other brands found for this formula.